OncoMatch/Clinical Trials/NCT06171282
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Is NCT06171282 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Recombinant oncolytic herpes simplex virus type Ⅰ (R130) for osteosarcoma.
Treatment: Recombinant oncolytic herpes simplex virus type Ⅰ (R130) — 9 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Osteosarcoma
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard treatment
Failure of standard treatment or patient unwillingness to receive other antitumor therapy
Cannot have received: any antitumor therapy
Any treatment for malignancy, including radiotherapy, chemotherapy and biological agents, must be discontinued 28 days prior to R130 treatment
Cannot have received: antitumor therapy (endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy, antitumor herbal therapy)
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L, platelets ≥ 80 × 10^9/L, hemoglobin ≥ 85 g/L
Kidney function
serum creatinine (Cr) and blood urea nitrogen (BUN) ≤ 1.5x ULN
Liver function
serum total bilirubin (TBIL) ≤ 2x ULN; ALT and AST ≤ 2.5x ULN (≤ 5x ULN if liver metastases)
laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelets (PLT) ≥ 80 × 10^9/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06171282 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any antitumor therapy, antitumor therapy (endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy, antitumor herbal therapy) disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages